Fujifilm adding $120M facility to its gene therapy operations in U.S.

Fujifilm Diosynth Biotechnologies in Texas
CDMO Fujifilm Diosynth Biotechnologies is quickly building up its gene and biologics manufacturing. (Fujifilm Diosynth Biotechnologies)

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation with plans for a $120 million addition to its facilities in Texas.

The company said its CDMO Fujifilm Diosynth Biotechnologies will add a building to its College Station, Texas campus which will include 6,000 square meters of new laboratories as well as eight new 500 / 2,000L single use bioreactors. A Fujifilm spokeswoman said the company intends to add 75 to 100 more scientists when the first phase of the new project is ready in 2021.

“Fujifilm is aggressively pursuing growth strategies with both capital investment and in-house development of high-efficiency and high-productivity new technologies,” the company said in a statement.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

RELATED: Fujifilm pays Biogen nearly $1B for Denmark biologics site

The announcement comes shortly after the CDMO completed a deal to buy a biologics plant in Denmark from Biogen, taking on 800 employees. Fujifilm and Biogen also agreed the CDMO would provide Biogen with the drugs the Cambridge, Massachusetts-based biotech had been manufacturing at the site. That includes its multiple sclerosis drug Tysabri.

The Japanese company has been on a spending spree in the last couple of years. In addition the the recent deals, it paid about $800 million to buy a pair of cell culture media units from Japan’s JXTG Holdings. In January, Fujifilm said it would invest about $90 million to expand its biologics plant in Morrisville, North Carolina, and the company is ramping up its induced pluripotent stem cell technologies for its own pipeline of regenerative drugs and intends to manufacture iPS cells for others.

The company says it expects the CDMO business to generate nearly a $1 billion by the end of fiscal year 2021, ending March 2022.

Suggested Articles

Johnson & Johnson will shell out at least $480 million to Emergent BioSolutions to produce millions of doses of its COVID-19 vaccine hopeful.

Despite the many HIV drugs available, some patients still can’t be successfully treated because they're drug-resistant. Now, they have a new option.

Sanofi and Regeneron have stopped their U.S. trial for Kevzara in COVID-19 after the drug showed no benefit in treating ventilated patients.